Product image of Olssa (Olmesartan Medoxomil, Amlodipine) supplied by GNH India

Olssa

Active Ingredient:
Olmesartan Medoxomil, Amlodipine
Origin:
EU

Olssa (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil, the active ingredient in Olssa, is a angiotensin II receptor blocker presented as a oral tablet for oral use. It treats hypertension, often in combination with a calcium‑channel blocker, and is intended for adult patients. GNH India supplies Olssa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH India supplies Olssa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Olssa combines two antihypertensive agents that act on the renin‑angiotensin system and vascular smooth‑muscle tone.

  • Hypertension: improves blood pressure control when monotherapy is insufficient.
  • Chronic kidney disease with hypertension: slows progression of proteinuria.
  • Heart failure with reduced ejection fraction: adjunctive therapy to reduce afterload.
  • Diabetes‑related hypertension: provides renal protective benefits.
  • High‑risk cardiovascular patients: lowers risk of stroke and myocardial infarction.
  • Elderly patients with isolated systolic hypertension: offers better tolerability.

How It Works

  • Olmesartan medoxomil blocks the binding of angiotensin II to the AT1 receptor, preventing vasoconstriction and aldosterone release. Amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation. The combined effect reduces peripheral resistance and lowers systemic blood pressure, addressing hypertension through complementary mechanisms.

Side Effects

Olssa may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Peripheral edema: swelling of ankles or feet.
  • Dizziness or light‑headedness: especially after the first dose.
  • Flushing: transient warmth sensation.
  • Fatigue: general tiredness.
  • Nausea: occasional upset stomach.

Serious or Rare Side Effects

  • Angio‑edema: swelling of face, lips or throat.
  • Severe hypotension: marked drop in blood pressure.
  • Hepatic dysfunction: elevated liver enzymes.
  • Acute kidney injury: sudden loss of kidney function.
  • Myocardial infarction: rare but reported.
  • Hyperkalemia: elevated potassium levels.

Precautions & Warnings

When prescribing Olssa, clinicians should consider several safety aspects.

  • Monitor blood pressure: ensure adequate control without excessive lowering.
  • Assess renal function: adjust use in patients with impaired kidneys.
  • Check electrolytes: especially potassium levels.
  • Review concomitant antihypertensives: avoid excessive additive effects.
  • Pregnancy warning: avoid use in pregnancy due to fetal toxicity.
  • Store at ambient temperature: keep below 25°C, protect from moisture and light.

Avoid Interactions

Olssa can interact with several drug classes, requiring careful management. Major Interactions (Avoid):\n- Potassium‑sparing diuretics: risk of hyper‑kalemia.

  • ACE inhibitors or other ARBs: additive hypotensive effect.
  • Strong CYP3A4 inhibitors: increased amlodipine levels.

Moderate Interactions (Monitor Closely)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive efficacy.
  • Lithium: altered renal clearance may increase toxicity.
  • Simvastatin: amlodipine can raise statin concentrations, increasing myopathy risk.

Frequently Asked Questions

Olssa is a fixed‑dose combination of olmesartan medoxomil and amlodipine that is prescribed to lower high blood pressure. It is used when monotherapy does not achieve target blood pressure, and it may also be chosen for patients with hypertension‑related kidney or cardiovascular risk.

Olmesartan medoxil is an angiotensin II receptor blocker. It selectively blocks AT‑1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release, which helps relax blood vessels and lower blood pressure.

The dose of Olssa is individualized by the prescribing clinician based on the patient’s blood‑pressure level, response, and tolerability. The prescriber determines the appropriate strength and dosing schedule.

Olssa is contraindicated in pregnancy because angiotensin‑II receptor blockers can cause fetal toxicity. Limited data exist for breastfeeding, and the drug is generally avoided unless the benefit outweighs potential risk.

To order Olssa, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and import documentation.

Olssa combines an ARB with a calcium‑channel blocker, offering complementary mechanisms. Compared with ACE‑inhibitor + CCB combos, it avoids cough associated with ACE inhibitors and provides consistent blood‑pressure control, though individual response may vary.

Olssa tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep out of reach of children.

Olssa is taken orally, usually once daily, with or without food. Patients should follow the prescribing clinician’s instructions regarding timing and whether to swallow the tablet whole.

Serious risks include angio‑edema, severe hypotension, acute kidney injury, and hyper‑kalemia. Patients should seek immediate medical attention if they experience swelling of the face or throat, dizziness, or sudden loss of kidney function.

Olssa should not be used by individuals with known hypersensitivity to olmesartan, amlodipine or any excipients, pregnant women, or patients with severe hepatic impairment. Caution is also advised for those with significant renal dysfunction.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Amlodipine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT